Amgen
Clinical trials sponsored by Amgen, explained in plain language.
A global biotechnology company developing therapies for cancer, kidney disease, and inflammation.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New drug aims to tame autoimmune hepatitis and cut steroid use
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 180 adults with autoimmune hepatitis, a condition where the immune system attacks the liver. The goal is to see if the drug can reduce liver inflammation and allow patients to take lower doses of steroids. Participants will receive e…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New combo therapy aims to boost platelets in immune disorder
Disease control Not yet recruitingThis phase 3 trial tests whether adding romiplostim to standard prednisone treatment improves platelet counts in adults with previously untreated primary immune thrombocytopenia (ITP). Participants receive either romiplostim plus prednisone or prednisone alone. The study measures…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug shows promise for sustained weight loss in type 2 diabetes
Disease control Not yet recruitingThis study tests a drug called maridebart cafraglutide (MariTide) in people who are overweight or obese and also have type 2 diabetes. The goal is to see if the drug can help with long-term weight loss and blood sugar control, and to check its safety over time. Participants recei…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug trial aims to tame rare inflammatory disease in kids
Disease control Not yet recruitingThis study tests a drug called inebilizumab in 15 children aged 2 to 17 who have IgG4-related disease, a rare condition that causes swelling and damage in organs. The drug is given through an IV and works by lowering certain immune cells to reduce inflammation. Researchers will c…
Phase: PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Leukemia shot could replace long IV drips
Disease control Not yet recruitingThis study tests if a shot (subcutaneous) of the drug blinatumomab works as well as the standard IV drip for adults with a certain type of leukemia (Ph-negative B-cell ALL). About 560 people who are in remission after initial chemo will get either the shot or the IV, along with m…
Phase: PHASE3 • Sponsor: Amgen • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC